Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic sclerosis-associated interstitial lung disease longitudinal observational treatment study
2008-000224-27Phase 4Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Aug 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone and cyclophosphamide in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and systemic sclerosis (SSc) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Change in percent predicted forced vital capacity (FVC) and Change in percent predicted diffusing capacity of the lung for carbon monoxide (DLCO). Started Aug 2008; status: completed.
02
Drugs
methylprednisolonecyclophosphamide
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2008-000224-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000224-27.